301211.SZ
亨迪药业
SZSE · Healthcare · C 制造业 · CN
CNY 11.75
−5.77%Year over year
Reported trailing growth
- Revenue
- +8.7%
- EBITDA
- —
- EBIT
- -42.7%
- EPS
- -54.3%
- Free cash flow
- +1.0%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.2%
- EBITDA
- -20.7%
- EBIT
- -34.5%
- Net income
- -34.8%
- EPS
- -43.3%
- Free cash flow
- +34.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026